Clinical Trial Update: A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo [Phase 2]

View source ↗

Summary

A Phase 2 trial, sponsored by Sanofi, evaluates vaccine responses in adults with atopic dermatitis treated with subcutaneous amlitelimab versus placebo; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 2 | Status: COMPLETED